NUCLEOSIDE ANALOGUES IN THE TREATMENT OF DECOMPENSATED HEPATIC CIRRHOSIS CAUSED BY HEPATITIS B VIRUS


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Chronic hepatic B virus (HBV) infection frequently leads to hepatic cirrhosis, whose decompensation reflects HBV reactivation under the influence of different exogenous and endogenous factors. The paper describes a case of reactivation of HBV infection in a female patient with chronic asymptomatc hepatic cirrhosis, rapidly developing liver cell failure and portal hypertension, as well as generalized vasculitis with the involvement of the aorta and its major branches (aortoarteritis) abolished by long-term entecavir treatment.

Full Text

Restricted Access

About the authors

T. N LOPATKINA

I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia

Email: lopatkina-tn@mail.ru

E. L TANASHCHUK

E.M. Tareyev Clinic of Nephrology, Internal and Occupational Diseases, University Clinical Hospital Three

D. T ABDURAKHMANOV

I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia

T. A BAIKOVA

I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia

References

  1. Абдурахманов Д., Ибрагимова М., Ильянкова А. и др. Возможности лечения декомпенсированного цирроза печени, обусловленного вирусом гепатита В. Врач 2002; 10: 30-31.
  2. Villeneuve J.P., Condreay L.D., Heathcote E.J. et al. Lamivudin treatment for decomprensated cirrhosis resаlting from chronic hepatitis B. Hepatology 2000; 31(1): 207-210.
  3. Fontana J., Perillo R., Hann H. et al. Determinants of survival in 133 patients with decompensated chronic hepatitis B treated with lamivudine (abstract). Hepatology 2000; 32: 221A.
  4. Yao F.Y., Terrault N.A., Freise A. et al. Lamivudine treatment is beneficial in patients with decompreasated cirrhosis and actively replicating hepatitis B virus infection awaiting liver transplantation: a comparative study using a matched, untreated cohort. Hepatology 2001; 34: 411-417.
  5. Liaw Y.F.,Sung J.J.Y., Chow W.C. et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N. Engl. J. Med. 2004; 351: 1521-1531.
  6. Keeffe E.B. End-Stage Liver Disease and Liver Transplantation: Role of Lamivudine Therapy in Patients With Chronic Hepatitis B. J. Med. Virology 2000; 61: 403-408.
  7. Tseng P.L., Lu S.N., Tung H.D. et al. Determinants of early mortality and benefits of lamivudine therapy in patients with hepatitis B virus-related decompensated liver cirrhosis. J. Viral Hepatitis 2005; 12: 386-392.
  8. Kapoor D., Guptan R.C., Wakil S.M. et al. Beneficial effects of lamivudine in hepatitis B virus - related decompensated cirrhosis. J. Hepatol. 2000; 33: 308-312.
  9. Мухин Н.А., Абдурахманов Д.Т., Лопаткина Т.Н. Цирроз печени в исходе вирусного гепатита В: лечение и прогноз. Практикующий врач 2005; 1: 5-7.
  10. Абдурахманов Д.Т. Хронический гепатит В и Д. М.: ГЭОТАР-Медиа, 2010.
  11. Знойко О.О. Место нуклеоз(т)идных аналогов в лечении хронического гепатита В. Гепатологический форум 2010; 1: 11-21.
  12. Fung S.K., Lok A.S.F. Management of patients with hepatitis B virus-induced cirrhosis. J. Hepatol. 2005; 42: S54-S64.
  13. Chang T.T., Liaw Y.F., Wu S.S. et al. Long-Term Entecavir Therapy Results in the Reversal of Fibrosis/Cirrhosis and Continued Histological Improvement in Patients with Chronic Hepatitis B. Hepatology 2010; 52: 886-893.
  14. Friedman S.L. Mechanisms of hepatic fibrogenesis. Gastroenterology 2008; 134: 1655-1669.
  15. Elsharkawy A.M., Oakley F., Mann D.A. The role and regulation of hepatic stellate cell apoptosis in reversal of liver fibrosis. Apoptosis 2005; 10: 927-939.
  16. Schiff E.R., Lee S.S., Chao Y.C. et al. Long-Term Treatment With Entecavir Induces Reversal of Advanced Fibrosis or Cirrhosis in Patients with Chronic Hepatitis B. Clin. Gastroenterol. Hepatol. 2011; 9: 274 -276.
  17. Brown A., Goodman Z. Hepatits B-associated fibrosis and fibrosis/cirrhosis regression with nucleoside and nucleotide analogs. Expert Rev. Gastroenterol. Hepatol. 2012; 6(2): 187-198.
  18. Lok A.S., McMahon B.J. Chronic hepatitis B. Hepatology 2007; 45: 507-539.
  19. Han S.H., Chang T.T., Chao Y.C. et al. Five years of continuos entecavir for nucleoside-naïve HBeAg(+) chronic hepatitis B: results from study ETV-901 (Abstract). Hepatology 2008; 48(suppl 1): 705A-706A.
  20. Liaw Y.F., Raptopoulou-Gigi M., Cheinquer H. et al. Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with evidence of hepatic decompensation. Hepatology 2011; 54(1): 91-100.
  21. Мазурчик Н.В., Огурцов П.П. Лечение цирроза печени в исходе хронического гепатита В. Гепатологический форум 2010; 1: 21-25.
  22. Прохорова М.В., Зверев К.В., Крель П.Е. Артериит Такаясу, ассоциированный с циррозом печени у больной с HBs-антигенемией. Тер. арх. 1992; 64: 103-104.
  23. Etgen T., Winbeck K., Conrad B., Sander D. Hemibalism with insular infarction as first manifestation of Takayasu’s arteritis in association with chronic hepatitis B. J. Neurol. 2003; 250(2): 226-229.
  24. Абдурахманов Д.Т., Русских А.В. Внепеченочные проявления хронической HBV-инфекции. Клин. фармакология 2003; 12: 18-22.
  25. Серов В.В., Апросина З.Г. Крель П.Е. Клиникоморфологическая характеристика внепеченочной патологии, обусловленной вирусом гепатита В. Клин. медицина 1989; 12: 3-9.
  26. Апросина З.Г., Попова И.В., Крель П.Е. и др. Своеобразное течение хронической генерализованной инфекции вируса гепатита В ( клинико-морфологическое наблюдение). Тер. арх. 1996; 11: 16-19.
  27. Апросина З.Г., Попов М.С., Гусейнова Л.А. и др. Синдром Рейно с гангреной концевых фаланг кистей и миокардит при вирусном (HBsAg-положительном) циррозе печени. Тер. арх. 1987; 2: 136-139.
  28. Семенкова Е.Н., Апросина З.Г., Лопаткина Т.Н. Узелковый периартериит и инфицирование вирусом гепатита В. Тер. арх. 1992; 11: 116-121.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies